NCT05659563 2026-03-19
EMPRESS
MedSIR
Phase 2 Completed
Clinical Trials
85 trialsNCT00893061 2026-03-17
MNEMOSYNE
Centre Oscar Lambret
Phase 3 Completed
NCT06982313 2026-03-11
Babytam long
Ente Ospedaliero Ospedali Galliera
Completed
NCT00003042 2026-02-20
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT05101564 2026-02-12
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Stanford University
Phase 2 Completed
NCT02668666 2026-01-20
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT07145827 2025-09-12
Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen
Uruk University
Phase NA Completed
NCT04300790 2025-07-29
METALLICA
MedSIR
Phase 2 Completed
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03219476 2025-04-29
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT03346200 2025-03-07
KARISMA2
Karolinska Institutet
Phase 2 Completed
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT00667121 2025-02-14
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline
Mayo Clinic
Completed
NCT00949598 2025-02-13
Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 3 Completed
NCT04079517 2025-02-06
Karisma-1
Karolinska Institutet
Phase 1/2 Completed
NCT02993159 2024-12-18
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
Northwestern University
Phase 2 Completed
NCT00002644 2024-12-11
IBIS-1
Queen Mary University of London
Phase 3 Completed
NCT03355157 2024-10-01
PADMA
GBG Forschungs GmbH
Phase 4 Completed
NCT02913430 2024-09-23
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT04129216 2024-05-07
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Johns Hopkins University
Phase 2 Completed
NCT03870399 2024-05-06
HORMONET
AC Camargo Cancer Center
Phase 2 Completed
NCT01298713 2023-09-06
Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT02584465 2023-09-06
REGOVAR
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT00866554 2023-06-02
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
CHU de Quebec-Universite Laval
Phase 2 Completed
NCT02285179 2022-10-12
Poseidon
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT03948568 2022-09-30
REaCT-RETT
Ottawa Hospital Research Institute
Phase 4 Completed
NCT02384239 2022-03-16
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
University of California, San Francisco
Phase 2 Completed
NCT00710970 2022-01-24
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
Baylor College of Medicine
Phase 2 Completed
NCT02586675 2022-01-21
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02988986 2021-09-22
ANETT
The Methodist Hospital Research Institute
Phase 2 Completed
NCT01220076 2021-03-12
TAM
Institut Cancerologie de l'Ouest
Phase 2 Completed
NCT02197897 2021-01-13
BCTamoxifen
Baylor College of Medicine
Phase 2 Completed
NCT01192308 2020-12-01
KINETAM
Radboud University Medical Center
Phase 1 Completed
NCT01950182 2020-07-15
SYSUCC-002
Sun Yat-sen University
Phase 3 Completed
NCT02866955 2020-03-09
EFESE
Institut de Cancérologie de Lorraine
Phase 2 Completed
NCT02291913 2020-02-17
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02344940 2019-09-24
TTOS
Shanghai Jiao Tong University School of Medicine
Phase 4 Completed
NCT03715413 2019-03-07
Analgesic Efficacy of Pulsed Radiofrequency in Non-cyclic Mastalgia
Mansoura University
Phase 2 Completed
NCT01638247 2018-09-19
MALE
GBG Forschungs GmbH
Phase 3 Completed
NCT01973660 2018-09-19
PAMELA
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT00687102 2018-09-12
Co-STAR
Wake Forest University Health Sciences
Phase 3 Completed
NCT01614210 2018-08-01
POWER PIINC
University of Utah
Phase 2 Completed
NCT02404844 2018-04-20
PIKTAM
University Hospital, Essen
Phase 2 Completed
NCT00194779 2018-03-12
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
University of Washington
Phase 2 Completed
NCT01612871 2018-03-05
MIRHO
Institut Claudius Regaud
Phase 4 Completed
NCT01127295 2018-03-02
PHACS
Institut Claudius Regaud
Phase 4 Completed
NCT01027416 2017-12-13
Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients
Roswell Park Cancer Institute
Phase NA Completed
NCT00900744 2017-08-25
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
Icahn School of Medicine at Mount Sinai
Completed
NCT00764322 2017-08-01
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed